NGAL

10 drugs in development·7 companies·1 clinical trial

Drug Pipeline by Phase

Approved(4)

Drug	Company
Exelderm	Journey Medical Corp (DERM)
naftifine	Amneal Pharmaceuticals, Inc. (AMRX)
Noxafil	Merck & Co., Inc. (MRK)
tavaborole	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(2)

Drug	Company
rezzayo	CorMedix Inc. (CRMD)
scy-247	SCYNEXIS INC (SCYX)

Unknown(4)

Drug	Company
amphotericin b liposome for injection (strength	NYMOX PHARMACEUTICAL CORP (NYMXF)
amphotericin b liposome for injection (strength	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
amphotericin b liposome for injection (trade name	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
amphotericin b liposome for injection (trade name	NYMOX PHARMACEUTICAL CORP (NYMXF)

BioSniper tracks 10 drugs in development for NGAL across 7 companies.

There are 1 clinical trial targeting NGAL tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.